Bio-Techne Expands Global GMP Manufacturing Network with New Bristol Facility to Advance Scalable Cell Therapy Development
Key Highlights
- ➤Bio-Techne opened a fully operational 10,000-square-foot GMP facility in Bristol
- ➤Bristol facility adds five ISO-8 and two ISO-7 cleanrooms
- ➤New site manufactures GMP-grade small molecules for global cell therapy developers
- ➤Bristol, St. Paul and Minneapolis network supports discovery through commercial manufacturing
Expert Statements
Kim Kelderman, President and Chief Executive Officer of Bio-Techne
“As the cell therapy field continues to mature, success increasingly depends on the ability to manufacture therapies consistently and at scale”
Kim Kelderman, President and Chief Executive Officer of Bio-Techne
“Our investment in Bristol demonstrates Bio-Techne's commitment to providing customers with the GMP materials, manufacturing expertise, and supply chain reliability needed to accelerate development and ultimately bring transformative therapies to patients worldwide.”
Will Geist, President of Bio-Techne's Protein Sciences Segment
“The opening of our Bristol facility represents more than additional manufacturing capacity”
Will Geist, President of Bio-Techne's Protein Sciences Segment
“It strengthens Bio-Techne's ability to serve as a long-term partner for cell therapy innovators by providing the quality, scale, and global support necessary to navigate the journey from discovery to commercial supply.”
Bio-Techne Expands Global GMP Manufacturing Network with New Bristol Facility to Advance Scalable Cell Therapy Development PR Newswire
* Investment strengthens Bio-Techne's global GMP manufacturing infrastructure for cell therapy applications * New Bristol facility expands GMP small molecule production capacity and complements recent investments in North America * Combined capabilities across Bristol, St. Paul and Minneapolis support customers from discovery through commercial manufacturing MINNEAPOLIS, Oct. 8, 2026 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH), a global provider of life science tools, reagents and diagnostic products, today announced the opening of a new manufacturing facility for Good Manufacturing Practice (GMP) grade small molecules in Bristol, United Kingdom, further expanding the company's global capabilities to support the rapidly growing cell therapy market. The investment reflects Bio-Techne's commitment to helping therapy developers address one of the industry's most pressing challenges: establishing scalable, reproducible manufacturing processes that can support programs from early development through commercialization.
Get started
Create a free account to read the full story.